Drug profile · INN
rimegepant sulfate
NURTEC ODT
rimegepant sulfate (NURTEC ODT) is a calcitonin gene-related peptide type 1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — rimegepant sulfate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
rimegepant sulfate (NURTEC ODT) is a calcitonin gene-related peptide type 1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Calcitonin gene-related peptide type 1 receptor antagonist
Primary target: Calcitonin gene-related peptide type 1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is rimegepant sulfate?
rimegepant sulfate (NURTEC ODT) is a calcitonin gene-related peptide type 1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for rimegepant sulfate?
NURTEC ODT is a marketed brand name for rimegepant sulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rimegepant sulfate?
rimegepant sulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.